# Plasma Biomarkers P-DAC, V1

> **NCT02050997** · — · TERMINATED · sponsor: **Cancer Trials Ireland** · enrollment: 169 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02050997
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-26
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 169 (ACTUAL)
- **Why stopped:** As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050997, "Plasma Biomarkers P-DAC, V1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02050997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*